National public health campaigns have attempted

Size: px
Start display at page:

Download "National public health campaigns have attempted"

Transcription

1 WINTER 2005 PREVENTIVE CARDIOLOGY 11 CLINICAL STUDY Knowledge of Cholesterol Levels and Targets in Patients With Coronary Artery Disease Susan Cheng, MD; 1,2 Judith H. Lichtman, MPH, PhD; 3 Joan M. Amatruda, RN; 4 Grace L. Smith, MPH; 1,5 Jennifer A. Mattera, MPH; 1 Sarah A. Roumanis, RN; 1 Harlan M. Krumholz, MD 1,4,6,7 Little is known about the extent to which patients are aware of nationally-recommended cholesterol and lipid subfraction targets. The authors interviewed 738 patients hospitalized with coronary artery disease to assess their knowledge of their low-density lipoprotein, high-density lipoprotein, and total cholesterol levels as well as corresponding national targets. Only 8%, 8%, and 43% of patients could recall their low-density lipoprotein, high-density lipoprotein, and total cholesterol values, respectively. Only 5%, 2%, and 50% could correctly name targets for these values. Knowledge of cholesterol targets was particularly poor among women, nonwhites, and patients without any college education. Patients with multiple cardiac risk factors and patients with a previous history of cardiovascular disease were no more knowledgeable about their cholesterol targets than those without these conditions. These findings suggest that current cholesterol education efforts appear inadequate, particularly for women, nonwhites, and patients without any college education. (Prev Cardiol. 2005;8:11 17) 2005 Le Jacq Ltd. From the Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT; 1 The Johns Hopkins University School of Medicine, Baltimore, MD; 2 Section of Chronic Disease Epidemiology, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT; 3 the Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT; 4 Department of Medicine, Yale University School of Medicine, New Haven, CT; 5 Section of Health Policy and Administration, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT; 6 and the Robert Wood Johnson Clinical Scholars Program, Yale University School of Medicine, New Haven, CT 7 Address for correspondence: Harlan M. Krumholz, MD, Yale University School of Medicine, 333 Cedar Street, Room I-456 SHM (P.O. Box ), New Haven, CT harlan.krumholz@yale.edu Manuscript received August 23, 2004; accepted September 14, ID: 3939 National public health campaigns have attempted to increase patient understanding of high blood cholesterol with the aim of decreasing its prevalence. Since its inception by the National Heart, Lung, and Blood Institute (NHLBI) in 1985, the National Cholesterol Education Program (NCEP) has implemented patient-based and population-based approaches to this goal. 1 6 Over the last decade, public health, pharmaceutical, and professional organizations such as the American Heart Association (AHA) have also sponsored initiatives encouraging patients to know their cholesterol levels and achieve target levels. Despite these efforts, early population studies have shown that many individuals remain unaware of their total cholesterol levels 7 11 ; however, the extent to which patients are aware of guideline-based cholesterol targets has never been reported. Although national guidelines emphasize the importance of low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels, it is also not known whether many patients know their LDL and HDL levels and recommended targets. Therefore, we evaluated knowledge of LDL, HDL, and total cholesterol levels and targets among patients hospitalized with coronary artery disease (CAD). We also sought to determine whether certain subgroups of CAD patients, defined by demographic or clinical characteristics, were particularly likely to lack knowledge of their cholesterol levels and targets. METHODS Setting and Subjects For this study, we used data from the Reinforcing Education About Cholesterol (REACH) study, a randomized trial of an educational intervention designed to improve compliance with national cholesterol targets in CAD patients. The REACH investigators screened consecutive patients admitted to Yale-New Haven Hospital in New Haven, CT from December 1998 January 2000 for enrollment. Patients aged years were evaluated for participation in the REACH study, within 24 hours of admission, for evidence of CAD defined as: current or prior myocardial infarction, current or prior coronary artery bypass graft surgery, current

2 12 PREVENTIVE CARDIOLOGY WINTER 2005 or prior percutaneous coronary intervention, or a coronary artery stenosis 70% documented by cardiac catheterization. Patients were excluded if they had contraindications to taking cholesterollowering medication or situations or conditions that would restrict their ability to participate in an interview, benefit from an educational program, or be followed up at the end of the study. The Institutional Review Board of the Yale University School of Medicine approved the study; all participants gave written informed consent. Data Collection As part of the REACH trial, baseline demographic and clinical variables from patients medical records were abstracted, including: cardiac risk factors, history of tests and procedures (cardiac catheterization, coronary artery bypass graft, and percutaneous coronary intervention), and history of cardiovascular (CVD) disease, (myocardial infarction, angina, cerebrovascular accident, and peripheral vascular disease). Upon enrollment, trained research staff interviewed all participants a mean of 3.7±3.4 days after admission to assess their baseline knowledge, attitudes, and behaviors related to CAD, as well as education level and cholesterol-lowering medication usage. Cholesterol Knowledge Measurements For this study, we analyzed baseline REACH data including responses to patient interviews. We defined reported knowledge of personal cholesterol levels as a positive response to the question, Can you tell me what your cholesterol levels are? and the ability to offer at least one numeric value when subsequently asked, What are they? Patients were asked to specify subfraction vs. total values. We considered patients able to recall their LDL, HDL, or total cholesterol level if they could name a numeric value for these measurements, respectively. We defined reported knowledge of cholesterol target levels as a positive response to the question, Can you tell me what your cholesterol levels should be? and the ability to name at least one numeric value when subsequently asked, What should they be? Patients were asked to specify subfraction vs. total values. Since all patients were admitted with CAD, the values they named were compared with the then current NCEP II target levels designated for patients in the highest NCEP risk group: LDL-C 100 mg/dl, HDL-C >35 mg/dl, and total cholesterol <200 mg/dl. 3 We considered patients to have correct knowledge of LDL or total cholesterol targets if they named a value 100 mg/dl or 200 mg/dl, respectively. Correct knowledge of their HDL target was considered if patients named a value 35 mg/dl. We repeated this evaluation using NCEP target levels designated for low, moderate, or high NCEP risk groups as they would have applied to patients before hospitalization. Statistical Analysis Dependent variables in the analysis included: reported knowledge of own levels; ability to recall own LDL-C level; ability to recall own HDL-C level; ability to recall own total cholesterol level; reported knowledge of target levels; ability to name correct LDL-C target; ability to name correct HDL-C target; and ability to name correct total cholesterol target. We used chi-square tests to evaluate bivariate associations between each dependent variable and patient demographic and clinical characteristics. Based on clinical relevance and the results of bivariate analyses, relevant characteristics (female sex, age 65 and older, nonwhite race, less than any college education, two or more NCEP risk factors, previous history of CVD, no cholesterol screening within the last 6 months, and not taking cholesterol-lowering medication) were selected and entered into a logistic regression model. To assess the independent relationship of each characteristic with the different cholesterol knowledge components, a separate model was constructed for each dependent variable. Statistical analyses were conducted with SAS statistical software, version 8.01 (SAS Institute Inc., Cary, NC). RESULTS Of the 2657 patients screened for participation in the REACH trial, 1172 were eligible. Of these patients, 432 were not enrolled due to refusal or discharge before being interviewed by research staff; these patients were similar to study patients with respect to sex, age, race, admission diagnosis, and length of stay. Baseline interviews were missing for two patients. Characteristics of the remaining 738 patients included in our study sample are given in Table I. Knowledge of Personal Cholesterol Levels Of the total sample, 45.3% reported knowing their cholesterol levels, and only 8.4%, 8.1%, and 42.8% of all patients could recall a value for their LDL, HDL, and total cholesterol levels, respectively (Table II). Patients who reported knowledge of and then could recall their personal cholesterol levels were more likely to be male, less than 65 years old, white, and college educated. Patients knowledgeable of their personal cholesterol levels were also more likely to have had their cholesterol screened within the last 6 months and more likely to be taking cholesterol-lowering medication. Having any single NCEP risk factor, any combination of two or more risk factors, or a previous history of CVD was not associated with knowledge of personal cholesterol levels. Patients with a history of diabetes mellitus, however, were less likely than those without diabetes to report knowing their personal cholesterol levels (33.0% vs. 50.7%, p<0.001) or to recall personal levels (LDL 4.5% vs. 10.2%, p<0.01; HDL 4.5% vs. 9.8%, p<0.05; total cholesterol 31.7% vs. 43.7%, p<0.001).

3 WINTER 2005 PREVENTIVE CARDIOLOGY 13 In logistic regression models testing for the independent effect of patient characteristics on knowledge of personal cholesterol levels, women (odds ratio [OR], 0.69; 95% confidence interval [CI], ), nonwhites (OR, 0.43; CI, ), and patients without any college education (OR, 0.54; CI, ) were less likely to report knowing their cholesterol levels. When specifically asked, patients without any college education were less likely than college-educated patients to recall any of their cholesterol levels (LDL OR, 0.43; CI, ; HDL OR, 0.44; CI, ; total OR, 0.69; CI, ). The same applied to patients without a cholesterol screening within the last 6 months as compared with patients with a recent screening (LDL OR, 0.28; CI, ; HDL OR, 0.19; CI, ; total OR, 0.16; CI, ). Patients aged 65 years (OR, 0.71; CI, ), nonwhites (OR, 0.40; CI, ), and patients not taking cholesterol-lowering medication (OR, 0.60; CI, ) were less likely to recall their total cholesterol levels. Knowledge of Target Cholesterol Levels Of the total sample, 54.9% of patients reported knowing their target cholesterol levels, and only 4.7%, 2.3%, and 49.5% of all patients could correctly name their LDL, HDL, and total cholesterol target levels, respectively (Table III). These rates did not differ when named values were evaluated using target levels defined by patients NCEP risk status before admission. Of all cholesterol target values named by patients, the majority were correct (Figure). Patients who reported knowing their targets and could then correctly name their target levels were more likely to be men, white, and have at least some college education. Patients who demonstrated knowledge of their targets were also more likely to have had a cholesterol screening within the last 6 months and to be taking cholesterol-lowering medication. Having any single NCEP risk factor, any combination of two or more risk factors, or any history of CVD were not associated with a greater knowledge of their targets. Patients with a history of diabetes mellitus were less likely than those without diabetes to report knowing their targets (48.2% vs. 57.6%, p<0.05) and correctly name their total cholesterol target (43.8% vs. 51.7%, p<0.05). Multivariate analysis showed that patients less likely to report knowing their cholesterol targets were aged 65 years (OR, 0.66; CI, ), nonwhite (OR, 0.46; CI, ), and without any college education (OR, 0.66; CI, ). When specifically asked, women were less likely than men to correctly name their LDL-C target (OR, 0.32; CI, ). Nonwhites (OR, 0.39; CI, ) and patients without a recent cholesterol screening (OR, 0.52; CI, ) were less likely to correctly name their total cholesterol target. Patients without any college education were less likely to Table I. Sample Characteristics CHARACTERISTICS N % Total Women Age (mean±sd) 63.3± Nonwhite race < Any college education NCEP CARDIAC RISK FACTORS Older age (men 45, women ) History of hypertension History of diabetes mellitus Current smoker HDL-C <35 mg/dl NCEP cardiac risk factors HISTORY OF CVD Myocardial infarction Angina Positive catheterization result Percutaneous coronary intervention Coronary artery bypass Cerebrovascular accident Peripheral vascular disease NCEP RISK CATEGORY History of diagnosed CVD No CVD history and 2 risk factors No CVD history and <2 risk factors CHOLESTEROL MANAGEMENT Cholesterol test in last months Taking medication NCEP=National Cholesterol Education Program; HDL-C=high-density lipoprotein cholesterol; CVD=cardiovascular disease (includes history of myocardial infarction, angina, positive catheterization result, percutaneous coronary intervention, coronary artery bypass, cerebrovascular accident, or peripheral vascular disease) correctly name their HDL (OR, 0.22; CI, ) or total (OR, 0.64; CI, ) cholesterol targets. Similarly, patients not taking cholesterol-lowering medication were less likely to correctly name their LDL (OR, 0.16; CI, ) or total (OR, 0.61; CI, ) cholesterol targets. DISCUSSION Our study demonstrates that individuals hospitalized with CAD have a poor knowledge of their cholesterol levels and targets. National education programs sponsored by organizations such as the NHLBI and AHA have promoted awareness of personal and target cholesterol levels, particularly among

4 14 PREVENTIVE CARDIOLOGY WINTER 2005 Table II. Knowledge of Personal Cholesterol Levels Compared Among Patient Subgroups RECALLED A VALUE REPORTED KNOWLEDGE LDL-C HDL-C TOTAL CHOLESTEROL CHARACTERISTICS N % N % N % N % Total Sex Women * 9 4.2* ** Men Age <65 years * * ** 65 years Race White * Nonwhite Education < Any college * * * * Any college Cholesterol management Cholesterol test in last * months No recent cholesterol test Taking medication Not taking medication LDL-C=low-density lipoprotein cholesterol; HDL-C=high-density lipoprotein cholesterol. *p<0.01; **p<0.05; p<0.001 Table III. Knowledge of Cholesterol Targets Compared Among Subgroups NAMED A CORRECT TARGET VALUE REPORTED KNOWLEDGE LDL-C HDL-C TOTAL CHOLESTEROL CHARACTERISTICS N % N % N % N % Total Sex Women * 4 1.9** ** ** Men Age <65 years years Race White * * Nonwhite Education < Any college Any college ) Cholesterol management Cholesterol test in last * ** ** * months No recent cholesterol test Taking medication * * * Not taking medication LDL-C=low-density lipoprotein cholesterol; HDL-C=high-density lipoprotein cholesterol. *p<0.001; **p<0.05; p<0.01

5 WINTER 2005 PREVENTIVE CARDIOLOGY 15 6% Percentage of all patients Percentage of all patients 5% 4% 3% 2% 1% 0% 3% 2% 1% Any value < >160 Named values for LDL-C target (mg/dl) 0% Any value < >55 Named values for HDL-C target (mg/dl) 60% Percentage of all patients 50% 40% 30% 20% 10% 0% Any value < >260 Named values for total cholesterol target (mg/dl) Figure. Distribution of named values for LDL-C (low-density lipoprotein cholesterol), HDL-C (high-density lipoprotein cholesterol), and total cholesterol targets

6 16 PREVENTIVE CARDIOLOGY WINTER 2005 individuals with cardiac risk factors or established CVD; however, only 45% of patients in this study reported knowing their cholesterol levels and only 55% reported knowing their targets. While similarly low rates of personal cholesterol awareness, ranging from 33% 60%, have been found in individuals with and without CAD, 7 9,12 14 the present study extends previous work by specifically investigating knowledge of nationally recommended targets in a CAD patient sample. Our findings suggest there remains much room for improving education of patients about their overall cholesterol status, including their target as well as personal cholesterol levels. Opportunities to improve cholesterol education efforts exist among high-risk patients in particular. In this study, a prior diagnosis of CVD did not enhance patients knowledge of their cholesterol levels or targets, nor did any single NCEP risk factor or any combination of two or more risk factors. Furthermore, we found that patients with diabetes were less likely to have knowledge of their personal or target cholesterol levels. Previous studies have reported similar findings concerning knowledge of personal cholesterol levels, 8,12,13 and these data together suggest that high-risk patients are not currently benefiting from cholesterol counseling and education any more than low-risk patients. Despite the importance of LDL-C and HDL-C, awareness of these cholesterol subfractions has never been reported. Our study found that <10% of patients with CAD could demonstrate a knowledge of their LDL and HDL levels or targets. These patients amounted to less than one fifth of those who knew their total cholesterol levels or targets. Greater knowledge of total cholesterol may be related to its recommended usage as an initial screening for hypercholesterolemia as well as an overall marker of cholesterol status in patients on cholesterol-lowering therapy. 4 NCEP guidelines, however, have repeatedly emphasized the importance of LDL-C in CAD risk reduction, 15 and HDL-C has been increasingly recognized as an important component of cholesterol management Our findings suggest that CAD patients remain focused on knowing their total cholesterol levels and targets to the extent that they are aware of lipid levels at all. Therefore, existing education and counseling strategies directed at high-risk patients need to further emphasize the importance of LDL-C and HDL-C. Prior work has indicated that knowledge of personal cholesterol levels is highest among males, whites, and individuals with a higher education level 7 10,12,13,19,20 ; our results demonstrate that knowledge of target cholesterol levels is also highest in these patient groups. Women, nonwhites, and patients without any college education in our study were less likely than their counterparts to report knowing their cholesterol levels or targets, and they were less likely to recall their cholesterol levels or correctly name targets when further questioned. More targeted cholesterol education efforts may be needed to reach these subgroups in particular. Whereas previous studies of patients without CAD have found older adults more likely to know their personal cholesterol levels than younger adults, 8,10,21 our data showed no significant difference in personal cholesterol knowledge between age groups after adjustment for sex, education, presence of multiple risk factors, history of CVD, recent cholesterol screening, and cholesterol-lowering medication status. In fact, adjusted analysis showed patients aged 65 years to be less likely than younger patients to report knowing their cholesterol targets. Age-related differences in knowledge of targets may also be due to inequalities in access to information, access to health care, or other factors not controlled for in this study. Our assessment of personal cholesterol knowledge was based on patients ability to recall values for their LDL, HDL, or total cholesterol. We used this conservative method for evaluating personal cholesterol knowledge since patients measurements before hospitalization were unavailable, and patients cholesterol levels measured during admission were not considered to be representative of their out-ofhospital measurements. 22 Previous assessments of personal cholesterol knowledge in non-hospitalized patients, however, have shown a correlation between self-reported cholesterol levels and corresponding outpatient laboratory measurements. 7,8,23 Our findings were limited to CAD patients admitted to the hospital with acute disease, which could have affected their ability to demonstrate knowledge of their health. While there exist no other data about patient knowledge of cholesterol targets or lipid subfractions for direct comparison, prior studies have found similarly low rates of personal cholesterol and blood pressure knowledge among non-hospitalized patients. 7,9,12,13,23 These studies also suggest that our findings, while limited to a single center, are likely to be supported by further investigations of cholesterol knowledge. Our sample did not include patients who were unable to provide informed consent or be interviewed and patients deemed unable to participate in or benefit from an educational program. Including such patients, however, would likely have resulted in even lower knowledge rates, further supporting the overall findings of this study. In conclusion, patients hospitalized with CAD have remarkably poor knowledge of their cholesterol levels and targets, particularly regarding lipid subfractions. Low rates of cholesterol knowledge are especially prevalent among women, nonwhites, and individuals without any college education. Increased patient-oriented counseling and more targeted education efforts may lead to an improved cholesterol knowledge among individuals at high risk for coronary events and, in turn, more effective patient-provider partnerships in the management of high blood cholesterol as a major modifiable risk factor.

7 WINTER 2005 PREVENTIVE CARDIOLOGY 17 Acknowledgments. This study was supported by a grant from Pfizer. Dr. Lichtman is a Goddess Fund Career Development Scholar. REFERENCES 1 Cleeman JI, Lenfant C. The National Cholesterol Education Program: progress and prospects. JAMA. 1998;280: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988;148: Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269: National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285: Bellicha T, McGrath J. Mass media approaches to reducing cardiovascular disease risk. Public Health Rep. 1990;105: Pieper RM, Arnett DK, McGovern PG, et al. Trends in cholesterol knowledge and screening and hypercholesterolemia awareness and treatment, The Minnesota Heart Survey. Arch Intern Med. 1997;157: Murdoch M, Wilt TJ. Cholesterol awareness after case-finding: do patients really know their cholesterol numbers? Am J Prev Med. 1997;13: Nieto FJ, Alonso J, Chambless LE, et al. Population awareness and control of hypertension and hypercholesterolemia. The Atherosclerosis Risk in Communities study. Arch Intern Med. 1995;155: Cholesterol screening and awareness behavioral risk factor surveillance system, Morb Mortal Wkly Rep. 1992;41: Luepker RV. Current status of cholesterol treatment in the community: the Minnesota Heart Survey. Am J Med. 1997;102: Ayanian JZ, Landon BE, Landrum MB, et al. Use of cholesterol-lowering therapy and related beliefs among middleaged adults after myocardial infarction. J Gen Intern Med. 2002;17: Ayanian JZ, Landrum MB, McNeil BJ. Use of cholesterollowering therapy by elderly adults after myocardial infarction. Arch Intern Med. 2002;162: Frank E, Winkleby MA, Fortmann SP, et al. Improved cholesterol-related knowledge and behavior and plasma cholesterol levels in adults during the 1980s. JAMA. 1992;268: Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol. 1998;82:3Q 12Q. 16 Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-density Lipoprotein Intervention Trial. Am J Cardiol. 2000;86:19L 22L. 17 Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341: Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279: Polednak AP. Awareness and use of blood cholesterol tests in year-olds by educational level. Public Health Rep. 1992;107: Sprafka JM, Burke GL, Folsom AR, et al. Hypercholesterolemia prevalence, awareness, and treatment in blacks and whites: the Minnesota Heart Survey. Prev Med. 1989;18: Blount BW, Brown JB. Retiree awareness of levels of blood pressure and cholesterol. Mil Med. 1996;161: Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol. 1993;22: Bairey Merz CN, Felando MN, Klein J. Cholesterol awareness and treatment in patients with coronary artery disease participating in cardiac rehabilitation. J Cardiopulm Rehabil. 1996;16:

The effect of cholesterol-related knowledge on patients' ability to reach target cholesterol levels

The effect of cholesterol-related knowledge on patients' ability to reach target cholesterol levels Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 2003 The effect of cholesterol-related knowledge on patients' ability

More information

( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )

( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD ) 005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,

More information

Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease

Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease Special Issue Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease Shung Chull Chae, M.D. Department of Internal Medicine / Division of Cardiology Kyungpook National University College

More information

Preventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform?

Preventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform? Journal of the American College of Cardiology Vol. 41, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00187-6

More information

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain

More information

in Two South Carolina Communities

in Two South Carolina Communities Self-Reported Frequency of Serum Cholesterol Testing, Awareness of Test Results, and Laboratory Cholesterol Values in Two South Carolina Communities GREGORY W. HEATH, DHSc, MPH ERKKI VARTIAINEN, MD,.PhD

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life

More information

Awareness, Accuracy, and Predictive Validity of Selfreported

Awareness, Accuracy, and Predictive Validity of Selfreported Awareness, Accuracy, and Predictive Validity of Selfreported Cholesterol in Women The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

More information

Data Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.

Data Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease. 1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association

More information

Patient characteristics Intervention Comparison Length of followup

Patient characteristics Intervention Comparison Length of followup ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing

More information

The American Diabetes Association estimates

The American Diabetes Association estimates DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

Low HDL and Diabetic Dyslipidemia

Low HDL and Diabetic Dyslipidemia The Lowdown: Low HDL and Diabetic Dyslipidemia Patients with diabetes commonly have a low-density lipoprotein cholesterol (LDL-C) no higher than that of the general population. What treatment is warranted

More information

Hae Sun Suh, B.Pharm., Ph.D. Jason N. Doctor, Ph.D.

Hae Sun Suh, B.Pharm., Ph.D. Jason N. Doctor, Ph.D. Podium Presentation, May 18, 2009 Comparison of Cardiovascular Event Rates in Subjects with Type II Diabetes Mellitus who Augmented from Statin Monotherapy to Statin Plus Fibrate Combination Therapy with

More information

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical

More information

LDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC

LDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC Am J Cardiol (2004);94:729-32 Relation of degree of physical activity to coronary artery calcium score in asymptomatic individuals with multiple metabolic risk factors M. Y. Desai, et al. Ciccarone Preventive

More information

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

RECOGNITION OF THE METABOLIC SYNDROME

RECOGNITION OF THE METABOLIC SYNDROME THE METABOLIC SYNDROME IN CLINICAL PRACTICE Michael H. Davidson, MD* ABSTRACT Patients with the metabolic syndrome remain at significantly elevated risk of morbidity and mortality associated with coronary

More information

A Systematic Approach to Improve Lipids in Coronary Artery Disease Patients Participating in a Cardiac Rehabilitation Program

A Systematic Approach to Improve Lipids in Coronary Artery Disease Patients Participating in a Cardiac Rehabilitation Program c e... A Systematic Approach to Improve Lipids in Coronary Artery Disease Patients Participating in a Cardiac Rehabilitation Program Sophia Boudoulas Meis, DO; Richard Snow, DO; Michelle LaLonde, MS; James

More information

Raising high-density lipoprotein cholesterol: where are we now?

Raising high-density lipoprotein cholesterol: where are we now? European Heart Journal Supplements (23) 5 (Supplement D), D17 D25 Raising high-density lipoprotein cholesterol: where are we now? Baylor College of Medicine, Houston, Texas, U.S.A. KEYWORDS Apolipoprotein;

More information

Journal of the American College of Cardiology Vol. 54, No. 25, by the American College of Cardiology Foundation ISSN /09/$36.

Journal of the American College of Cardiology Vol. 54, No. 25, by the American College of Cardiology Foundation ISSN /09/$36. Journal of the American College of Cardiology Vol. 54, No. 25, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.005

More information

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen

More information

Diabetes mellitus is a leading cause of morbidity and

Diabetes mellitus is a leading cause of morbidity and Clinical Guidelines Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians Vincenza Snow, MD; Mark D. Aronson, MD; E. Rodney

More information

Supplement materials:

Supplement materials: Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction

More information

Treatment to reduce cardiovascular risk: multifactorial management

Treatment to reduce cardiovascular risk: multifactorial management Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University

More information

Research Article The Effect of Elevated Triglycerides on the Onset and Progression of Coronary Artery Disease: A Retrospective Chart Review

Research Article The Effect of Elevated Triglycerides on the Onset and Progression of Coronary Artery Disease: A Retrospective Chart Review Cholesterol Volume 2015, Article ID 292935, 5 pages http://dx.doi.org/10.1155/2015/292935 Research Article The Effect of Elevated Triglycerides on the Onset and Progression of Coronary Artery Disease:

More information

New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines

New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular

More information

Hypertension awareness, treatment, and control

Hypertension awareness, treatment, and control O r i g i n a l P a p e r Prevalence of Self-Reported High Blood Pressure Awareness, Advice Received From Health Professionals, and Actions Taken to Reduce High Blood Pressure Among US Adults Healthstyles

More information

Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study

Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular

More information

Statistical Fact Sheet Populations

Statistical Fact Sheet Populations Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total

More information

Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events

Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts

More information

1. Which one of the following patients does not need to be screened for hyperlipidemia:

1. Which one of the following patients does not need to be screened for hyperlipidemia: Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:

More information

Statin pretreatment and presentation patterns in patients with acute coronary syndromes

Statin pretreatment and presentation patterns in patients with acute coronary syndromes Brief Report Page 1 of 5 Statin pretreatment and presentation patterns in patients with acute coronary syndromes Marcelo Trivi, Ruth Henquin, Juan Costabel, Diego Conde Cardiovascular Institute of Buenos

More information

High serum cholesterol is a risk factor for coronary

High serum cholesterol is a risk factor for coronary Impact of a Low-Cost Intervention to Increase Cholesterol Awareness Among Older Patients Maureen Murdoch, MD, MPH, Sheila A. Sheridan, MS, RN, CNS, Monica Lavin Doeden, MS, RD, Timothy J. Wilt, MD, MPH,

More information

APPENDIX F: CASE REPORT FORM

APPENDIX F: CASE REPORT FORM APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more

More information

The Heart of a Woman. Karen E. Friday, M.D. Associate Professor of Medicine Section of Endocrinology Louisiana State University School of Medicine

The Heart of a Woman. Karen E. Friday, M.D. Associate Professor of Medicine Section of Endocrinology Louisiana State University School of Medicine The Heart of a Woman Karen E. Friday, M.D. Associate Professor of Medicine Section of Endocrinology Louisiana State University School of Medicine American Heart Association Women, Heart Disease and Stroke

More information

CLINICAL. Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population

CLINICAL. Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population Jennifer S. Schultz, PhD; John C. O Donnell, PhD; Ken L. McDonough, MD;

More information

Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus

Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus C. Noel Bairey Merz MD, FACC, FAHA Professor and Women s Guild Endowed Chair Director, Barbra Streisand Women

More information

On May 2001, the Third Adult

On May 2001, the Third Adult THE RISK OF DIABETES: CAN WE IMPACT CHD THROUGH THE ATP III CHOLESTEROL GUIDELINES? * Based on a presentation given by Steven M. Haffner, MD, MPH ABSTRACT Diabetes has been recognized among diabetologists

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

Ischemic Cardiovascular Disease in Persons with Human Immunodeficiency Virus Infection

Ischemic Cardiovascular Disease in Persons with Human Immunodeficiency Virus Infection HIV/AIDS MAJOR ARTICLE Ischemic Cardiovascular Disease in Persons with Human Immunodeficiency Virus Infection Max H. David, 1,3 Richard Hornung, 2 and Carl J. Fichtenbaum 1 1 Department of Medicine, Division

More information

Threshold Level or Not for Low-Density Lipoprotein Cholesterol

Threshold Level or Not for Low-Density Lipoprotein Cholesterol ... SYMPOSIA PROCEEDINGS... Threshold Level or Not for Low-Density Lipoprotein Cholesterol Based on a debate between Philip J. Barter, MD, PhD, FRACP, and Frank M. Sacks, MD Debate Summary As drugs, such

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines

More information

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for + Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics

More information

Attendance rates and outcomes of cardiac rehabilitation in Victoria, 1998

Attendance rates and outcomes of cardiac rehabilitation in Victoria, 1998 Attendance rates and outcomes of cardiac rehabilitation in Victoria, 1998 CARDIOVASCULAR DISEASE is the leading cause of death in Australia, causing more than 40% of all deaths in 1998. 1 Cardiac rehabilitation

More information

Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T

Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T Record Status This is a critical abstract of an economic evaluation

More information

Analyzing Coronary Heart Disease Risk Factors and Proper Clinical Prescription of Statins. Peter Thorne

Analyzing Coronary Heart Disease Risk Factors and Proper Clinical Prescription of Statins. Peter Thorne Abstract Analyzing Coronary Heart Disease Risk Factors and Proper Clinical Prescription of Statins Peter Thorne A sample of adults participating in the first 7 months of visit 5 of the Atherosclerosis

More information

Section Editor Mason W Freeman, MD

Section Editor Mason W Freeman, MD Official reprint from UpToDate www.uptodate.com 2015 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek

More information

New Paradigms in Predicting CVD Risk

New Paradigms in Predicting CVD Risk New Paradigms in Predicting CVD Risk Imaging as an Integrator of Lifetime Risk Exposure Michael J. Blaha MD MPH Presented by: Michael J. Blaha September 24, 2014 1 Talk Outline Risk factors vs. Disease

More information

Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease

Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease Iana I. Simova, MD; Stefan V. Denchev, PhD; Simeon I. Dimitrov, PhD Clinic of Cardiology, University Hospital Alexandrovska,

More information

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic

More information

The Role of Cardiac Rehabilitation in Recovery & Secondary Prevention. Loren M Stabile, MS Cardiac & Pulmonary Rehab Program Manager

The Role of Cardiac Rehabilitation in Recovery & Secondary Prevention. Loren M Stabile, MS Cardiac & Pulmonary Rehab Program Manager The Role of Cardiac Rehabilitation in Recovery & Secondary Prevention Loren M Stabile, MS Cardiac & Pulmonary Rehab Program Manager Objectives Core Components of Cardiac Rehab Program CR Indications &

More information

The Framingham Coronary Heart Disease Risk Score

The Framingham Coronary Heart Disease Risk Score Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although

More information

Journal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20.

Journal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20. Journal of the American College of Cardiology Vol. 35, No. 4, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00643-9 Early

More information

ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW

ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):

More information

Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population

Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population The Framingham Heart Study ORIGINAL INVESTIGATION Donald M. Lloyd-Jones, MD; Christopher J. O Donnell, MD, MPH; Ralph

More information

ZEUS Trial ezetimibe Ultrasound Study

ZEUS Trial ezetimibe Ultrasound Study Trial The lower, The better Is it True for Plaque Regression? Statin alone versus Combination of Ezetimibe and Statin Juntendo University, Department of Cardiology, Tokyo, Japan Katsumi Miyauchi, Naohisa

More information

Hyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH

Hyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the

More information

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives

More information

LIST OF ABBREVIATIONS

LIST OF ABBREVIATIONS Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

The Impact of Smoking on Acute Ischemic Stroke

The Impact of Smoking on Acute Ischemic Stroke Smoking The Impact of Smoking on Acute Ischemic Stroke Wei-Chieh Weng, M.D. Department of Neurology, Chang-Gung Memorial Hospital, Kee-Lung, Taiwan Smoking related mortality Atherosclerotic vascular disease

More information

New Cholesterol Guidelines What the LDL are we supposed to do now?!

New Cholesterol Guidelines What the LDL are we supposed to do now?! New Cholesterol Guidelines What the LDL are we supposed to do now?! Michael D. Shapiro Assistant Professor of Medicine and Radiology Knight Cardiovascular Institute Oregon Health & Science University 2013

More information

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

Central pressures and prediction of cardiovascular events in erectile dysfunction patients Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,

More information

Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease

Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease MAK Akanda 1, KN Choudhury 2, MZ Ali 1, MK Kabir 3, LN Begum 4, LA Sayami 1 1 National Institute of Cardiovascular

More information

Prevalence of Low Low-Density Lipoprotein Cholesterol With Elevated High Sensitivity C-Reactive Protein in the U.S.

Prevalence of Low Low-Density Lipoprotein Cholesterol With Elevated High Sensitivity C-Reactive Protein in the U.S. Journal of the American College of Cardiology Vol. 53, No. 11, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.12.010

More information

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were

More information

Intercommunale de Santé Publique du Pays de Charleroi, Charleroi, Belgium 2

Intercommunale de Santé Publique du Pays de Charleroi, Charleroi, Belgium 2 Lipid Abnormalities Remain High among Treated Hypertensive Patients with Stable CHD: Results of the Dyslipidemia International Study (DYSIS) II Belgium Michel Guillaume 1, Eric Weber 2, Johan De Sutter

More information

Statin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines

Statin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines Drugs Aging (2015) 32:87 93 DOI 10.1007/s40266-014-0238-5 CURRENT OPINION Statin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines Yitzchak Weinberger Benjamin H. Han Published

More information

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Trends in Clinical, Demographic, and Biochemical Characteristics of Patients with Acute Myocardial Infarction from 2003 to 2008: A Report from the American Heart Association Get with the Guidelines Coronary

More information

Landmark Clinical Trials.

Landmark Clinical Trials. Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug

More information

... CPE/CNE QUIZ... CPE/CNE QUESTIONS

... CPE/CNE QUIZ... CPE/CNE QUESTIONS CPE/CNE QUESTIONS Continuing Pharmacy Education Accreditation The Virginia Council on Pharmaceutical Education is approved by the American Council on Pharmaceutical Education as a provider of continuing

More information

Older individuals are at greatest risk for developing and

Older individuals are at greatest risk for developing and Decade Long Trends (2001 2011) in Duration of Pre-Hospital Delay Among Elderly Patients Hospitalized for an Acute Myocardial Infarction Raghavendra P. Makam, MD, MPH; Nathaniel Erskine, BS; Jorge Yarzebski,

More information

Risk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium

Risk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium Risk Stratification of ACS Patients Frans Van de Werf, MD, PhD University of Leuven, Belgium Which type of ACS patients are we talking about to day? 4/14/2011 STEMI and NSTEMI in the NRMI registry from

More information

Rates and patterns of participation in cardiac rehabilitation in Victoria

Rates and patterns of participation in cardiac rehabilitation in Victoria Rates and patterns of participation in cardiac rehabilitation in Victoria Vijaya Sundararajan, MD, MPH, Stephen Begg, MS, Michael Ackland, MBBS, MPH, FAPHM, Ric Marshall, PhD Victorian Department of Human

More information

LAMIS (Livalo in AMI Study)

LAMIS (Livalo in AMI Study) JCR 2018. 12. 8 LAMIS (Livalo in AMI Study) Young Joon Hong Division of Cardiology, Chonnam National University Hospital Gwangju, Korea Trend of hypercholesterolemia in Korea < Prevalence of hypercholesterolemia

More information

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical

More information

ORIGINAL INVESTIGATION

ORIGINAL INVESTIGATION ORIGINAL INVESTIGATION Do Subspecialists Working Outside of Their Specialty Provide Less Efficient and Lower-Quality Care to Hospitalized Patients Than Do Primary Care Physicians? Scott R. Weingarten,

More information

Nearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III

Nearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated

More information

nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck

nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck Scottish Medicines Consortium Resubmission nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck New formulation 6 January 2006 The Scottish Medicines Consortium

More information

Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients

Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract

More information

Guidelines on cardiovascular risk assessment and management

Guidelines on cardiovascular risk assessment and management European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine

More information

Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany

Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany The demographic issue Life expectancy is increasing Patients are getting

More information

In 2001, the National Cholesterol Education Program

In 2001, the National Cholesterol Education Program At a Glance Practical Implications p 330 Author Information p 333 Full text and PDF www.ajpblive.com Lipid Management When Converting Fluvastatin to Pravastatin: Medication Use Evaluation Original Research

More information

Mode of admission and its effect on quality indicators in Belgian STEMI patients

Mode of admission and its effect on quality indicators in Belgian STEMI patients 2015 Mode of admission and its effect on quality indicators in Belgian STEMI patients Prof dr M Claeys National Coordinator STEMI registry 29-6-2015 Background The current guidelines for the management

More information

Heidi Mochari-Greenberger, Ph.D., M.P.H., 1 Thomas Mills, M.S., 2 Susan L. Simpson, Ph.D., 2 and Lori Mosca, M.D., M.P.H., Ph.D. 1

Heidi Mochari-Greenberger, Ph.D., M.P.H., 1 Thomas Mills, M.S., 2 Susan L. Simpson, Ph.D., 2 and Lori Mosca, M.D., M.P.H., Ph.D. 1 JOURNAL OF WOMEN S HEALTH Volume 19, Number 7, 2010 ª Mary Ann Liebert, Inc. DOI: 10.1089=jwh.2009.1749 Original Article Knowledge, Preventive Action, and Barriers to Cardiovascular Disease Prevention

More information

Division of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan

Division of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan Association between continuously elevated C-reactive protein and restenosis after percutaneous coronary intervention using drug-eluting stent in angina patients Division of Cardiovascular Medicine, Jichi

More information

Quality Payment Program: Cardiology Specialty Measure Set

Quality Payment Program: Cardiology Specialty Measure Set Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for

More information

Is it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany

Is it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany Is it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany Is it worth offering cardiovascular disease prevention to the elderly?

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Pokharel Y, Tang F, Jones PG, et al. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in cardiology practices

More information

8/15/2018. Promoting Education, Referral and Treatment for Patients Presenting with Metabolic Syndrome. Metabolic Syndrome.

8/15/2018. Promoting Education, Referral and Treatment for Patients Presenting with Metabolic Syndrome. Metabolic Syndrome. Promoting Education, Referral and Treatment for Patients Presenting with Metabolic Syndrome Diagnostic Criteria (3/5) Metabolic Syndrome Key Facts JAN BRIONES DNP, APRN, CNP FAMILY NURSE PRACTITIONER Abdominal

More information

Low fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease

Low fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease (2002) 16, 837 841 & 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Low fractional diastolic pressure in the ascending aorta increased the risk

More information

Acute Reperfusion Therapy in STelevation Myocardial Infarction from

Acute Reperfusion Therapy in STelevation Myocardial Infarction from Dominican Scholar Collected Faculty and Staff Scholarship Faculty and Staff Scholarship 2007 Acute Reperfusion Therapy in STelevation Myocardial Infarction from 1994-2003 Brahmajee K. Nallamouthu Health

More information

Atherosclerotic Disease Risk Score

Atherosclerotic Disease Risk Score Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,

More information

ORIGINAL INVESTIGATION

ORIGINAL INVESTIGATION Temporal Trends (1986-1997) in Cholesterol Level Assessment and Management Practices in Patients With Acute Myocardial Infarction A Population-Based Perspective ORIGINAL INVESTIGATION Jorge Yarzebski,

More information

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology

More information

The TNT Trial Is It Time to Shift Our Goals in Clinical

The TNT Trial Is It Time to Shift Our Goals in Clinical The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia

More information